PET/MR scans for newly diagnosed NK/T-cell lymphoma staging
Part of Cancer clinical trials.
This trial studies whether special imaging with PET/MR can help stage (find the extent of) and evaluate treatment effectiveness in people newly diagnosed with NK/T-cell lymphoma. It may help doctors choose the right treatment plan and track how well therapy is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of NK/T-cell lymphoma based on the WHO 2016 criteria
- You are between 14 and 70 years old
- You have not had any prior treatment for NK/T-cell lymphoma
- You can take part in study procedures and follow the research plan (and give written consent)
- Your overall health function is good enough (ECOG 0 to 2) and you’re expected to live at least 6 months
- You can safely have PET/MR scanning (no major scan safety issues like certain implants)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special PET scan to look for a protein called Granzyme B in your body, which may help predict how well treatment will work in T-NK cell lymphoma. It aims to see if this imaging can guide treatment decisions.
This study uses artificial intelligence to analyze PET/CT scans from people with T-NK cell lymphoma. It aims to improve diagnosis, predict how well treatment will work, and forecast outcomes.
This trial uses PET scans and EBV DNA levels to personalize treatment for patients with early-stage nasal NK/T cell lymphoma. It aims to reduce side effects by adjusting therapy based on how well the cancer responds.
This trial looks at whether PET/CT scans can better predict outcomes in people with fast-growing lymphoma. If you are newly diagnosed and receiving standard treatment, the study may help refine how response is evaluated.
This study tests whether a new type of PET/MRI scan can help doctors see how well breast cancer treatment is working. It is a platform study, meaning it can evaluate different treatments, but the focus is on using this advanced imaging to monitor response.
This study tests a newer type of PET/MR scan using a special tracer (68Ga-Pentixafor) to see if it can find lymphoma and multiple myeloma lesions better than the standard scan. The scan is painless and takes about 30 minutes, and it might help doctors see the cancer more clearly.
Hear when a new NK T-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.